Michael Chez to Treatment Outcome
This is a "connection" page, showing publications Michael Chez has written about Treatment Outcome.
Connection Strength
0.485
-
A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism. J Autism Dev Disord. 2020 May; 50(5):1532-1538.
Score: 0.147
-
Effectiveness and safety of perampanel by concomitant antiseizure medications: Insights from the real-world PERMIT Extension study. Epilepsy Behav. 2025 Oct; 171:110651.
Score: 0.053
-
Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004 Mar; 19(3):165-9.
Score: 0.048
-
Outcome measures for clinical drug trials in autism. CNS Spectr. 2004 Jan; 9(1):36-47.
Score: 0.047
-
Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002 Nov; 17(11):833-7.
Score: 0.044
-
PROVE: Retrospective, non-interventional, Phase IV study of perampanel in real-world clinical care of patients with epilepsy. Epilepsia Open. 2022 06; 7(2):293-305.
Score: 0.042
-
Secretin and autism: a two-part clinical investigation. J Autism Dev Disord. 2000 Apr; 30(2):87-94.
Score: 0.036
-
Clinical experience of three pediatric and one adult case of spike-and-wave status epilepticus treated with injectable valproic acid. J Child Neurol. 1999 Apr; 14(4):239-42.
Score: 0.034
-
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019 08; 154:13-20.
Score: 0.034